Roche Keeps Lifecycle Management In Motion For Oncology Portfolio

The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics